Valneva IPO Presentation Deck

VLA2001: Development Outlook Pivotal Phase 3 Trial Initiated ■ Pivotal Phase 3 is a randomized, observer-blind, controlled, comparative immunogenicity trial in ~ 4,000 adults Immunogical comparison against a licensed vaccine to reasonably predict efficacy (superiority of VLA2001 in a two-dose immunization schedule four weeks apart - GMTs of neutralising antibodies, at two weeks after the second vaccination) Study conducted in UK supported by DHSC/NIHR, including funding Protocol agreed with MHRA; discussion with other regulatory bodies ongoing ■ Additional studies planned Booster studies (including reduced booster dose) Valneva - Roadshow Presentation April 2021 32

View entire presentation